ECHOIQ LIMITED — Capital/Financing Update 2022

Oct 6, 2022

Market Announcement

==> picture [33 x 50] intentionally omitted <==

7 October 2022

==> picture [451 x 5] intentionally omitted <==

Echo IQ Limited (ASX: EIQ) – Suspension from Quotation

Description

The securities of Echo IQ Limited (‘EIQ’) will be suspended from quotation immediately under Listing Rule 17.2, at the request of EIQ, pending the release of an announcement regarding the outcome of its proposed capital raising and corporate transaction.

Issued by

Renee Hutchens

Adviser, Listings Compliance (Sydney)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

7 October 2022 ASX Limited

==> picture [146 x 26] intentionally omitted <==

7 October 2022

Renee Hutchens Adviser, Listing Compliance 20 Bridge Street Sydney NSW 2000

By Email: tradinghaltssydney@asx.com.au;

Dear Renee

Request for Voluntary Suspension

AI and Medical Technology company Echo IQ Limited (the Company) (ASX:EIQ) hereby requests that its securities be immediately suspended from quotation.

In accordance with ASX Listing Rule 17.2, the Company provides the following information:

• a) As set out in its request for trading halt dated 5 October 2022, Echo IQ is currently completing a capital raising and corporate transaction.

• b) Echo IQ requests that the voluntary suspension remain in place until the company releases an announcement in relation to the outcome of the proposed capital raising and corporate transaction.

• c) The Company expects the suspension to last until Wednesday 12 October 2022.

• d) Echo IQ is not aware of any reason why the voluntary suspension should not be granted or of any other information necessary to inform the market about the suspension.

If you have any questions regarding this matter, please contact Jessamyn Lyons, Company Secretary on 08 6245 2050.

Authorised for release by the Board of Directors of Echo IQ Limited.

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

==> picture [596 x 114] intentionally omitted <==